


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
HSMN NewsFeed - 11 Dec 2006
Watson Appoints Thomas Giordano as Senior Vice President, Chief Information Officer
Watson Appoints Thomas Giordano as Senior Vice President, Chief Information Officer
HSMN NewsFeed - 11 Dec 2006
Advanced Life Sciences Announces Election of Theron (Ted) E. Odlaug, Ph.D. to Its Board of Directors
Advanced Life Sciences Announces Election of Theron (Ted) E. Odlaug, Ph.D. to Its Board of Directors
HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
HSMN NewsFeed - 11 Dec 2006
Xeloda(R) Combination Meets Primary Endpoint in International Phase III Advanced Colorectal Cancer Study
Xeloda(R) Combination Meets Primary Endpoint in International Phase III Advanced Colorectal Cancer Study
HSMN NewsFeed - 11 Dec 2006
New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML
New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML
HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
HSMN NewsFeed - 7 Dec 2006
Norman C. Payson, M.D., Elected to Board of Directors of Idenix Pharmaceuticals
Norman C. Payson, M.D., Elected to Board of Directors of Idenix Pharmaceuticals
HSMN NewsFeed - 7 Dec 2006
HRA Pharma Commences US Phase III Trial of Second-Generation Emergency Contraceptive
HRA Pharma Commences US Phase III Trial of Second-Generation Emergency Contraceptive
HSMN NewsFeed - 6 Dec 2006
Jury Finds Insmed Infringed Patents Owned By Genentech And Exclusively Licensed to Tercica
Jury Finds Insmed Infringed Patents Owned By Genentech And Exclusively Licensed to Tercica
HSMN NewsFeed - 5 Dec 2006
Schering-Plough Enters Licensing Agreement to Market Prescription MiraLAX(R) Over-The-Counter
Schering-Plough Enters Licensing Agreement to Market Prescription MiraLAX(R) Over-The-Counter
HSMN NewsFeed - 5 Dec 2006
Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce Out-licensing of Aminocandin Anti-fungal
Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce Out-licensing of Aminocandin Anti-fungal
HSMN NewsFeed - 5 Dec 2006
Healtheuniverse Announces Appointment of Richard Tabizon to Managing Director of Asian Operations
Healtheuniverse Announces Appointment of Richard Tabizon to Managing Director of Asian Operations
HSMN NewsFeed - 5 Dec 2006
Ambit Biosciences Appoints Kerry Kelly, J.D., as Vice President and General Counsel
Ambit Biosciences Appoints Kerry Kelly, J.D., as Vice President and General Counsel
HSMN NewsFeed - 5 Dec 2006
Lexicon Genetics Files Investigational New Drug Application for LX1031 in Irritable Bowel Syndrome
Lexicon Genetics Files Investigational New Drug Application for LX1031 in Irritable Bowel Syndrome
HSMN NewsFeed - 5 Dec 2006
Micromet, Inc. and Serono Amend Collaboration Agreement and Continue Development of Adecatumumab (MT201)
Micromet, Inc. and Serono Amend Collaboration Agreement and Continue Development of Adecatumumab (MT201)
HSMN NewsFeed - 4 Dec 2006
King Pharmaceuticals Board Names Brian Markison to Succeed Ted Wood as Chairman
King Pharmaceuticals Board Names Brian Markison to Succeed Ted Wood as Chairman
HSMN NewsFeed - 4 Dec 2006
Alpharma Names Executive Vice President, Corporate and Business Development
Alpharma Names Executive Vice President, Corporate and Business Development
HSMN NewsFeed - 4 Dec 2006
PeriCor Therapeutics Mourns the Loss of Ross Dixon, Ph.D., Vice President, Pharmaceutical Development
PeriCor Therapeutics Mourns the Loss of Ross Dixon, Ph.D., Vice President, Pharmaceutical Development
HSMN NewsFeed - 4 Dec 2006
New Atlanta-Based Pharmaceutical Company Focuses on Central Nervous System
New Atlanta-Based Pharmaceutical Company Focuses on Central Nervous System
HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
HSMN NewsFeed - 4 Dec 2006
Merck and Neuroptix Collaborate on Early Alzheimer's Diagnostics Using Laser Eye Scanning
Merck and Neuroptix Collaborate on Early Alzheimer's Diagnostics Using Laser Eye Scanning
HSMN NewsFeed - 4 Dec 2006
Bayhill Therapeutics Names Paul Westberg Vice President of Business Development
Bayhill Therapeutics Names Paul Westberg Vice President of Business Development
HSMN NewsFeed - 4 Dec 2006
LUNESTA(R) Perimenopause-Menopause Study Published in Journal of Obstetrics and Gynecology
LUNESTA(R) Perimenopause-Menopause Study Published in Journal of Obstetrics and Gynecology
HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
HSMN NewsFeed - 4 Dec 2006
Janus Pharmaceuticals Inc. Announces Successful Phase II Study in Shingles
Janus Pharmaceuticals Inc. Announces Successful Phase II Study in Shingles
HSMN NewsFeed - 4 Dec 2006
Risk of Heart Attack Significantly Reduced in About 90 days by Modern Combination of Drugs
Risk of Heart Attack Significantly Reduced in About 90 days by Modern Combination of Drugs
HSMN NewsFeed - 1 Dec 2006
AmerisourceBergen Acquires Access M.D., Expanding Its Specialty Business into Canada
AmerisourceBergen Acquires Access M.D., Expanding Its Specialty Business into Canada
HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
HSMN NewsFeed - 30 Nov 2006
Cardinal Health Announces Plans to Sell $1.8 Billion Pharmaceutical Technologies and Services Segment
Cardinal Health Announces Plans to Sell $1.8 Billion Pharmaceutical Technologies and Services Segment
HSMN NewsFeed - 30 Nov 2006
Sirtris Pharmaceuticals Obtains Exclusive Rights to Key Sirtuin Technology from MIT
Sirtris Pharmaceuticals Obtains Exclusive Rights to Key Sirtuin Technology from MIT
HSMN NewsFeed - 29 Nov 2006
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
HSMN NewsFeed - 28 Nov 2006
Abraxis BioScience Receives FDA Approval for Ampicillin and Sulbactam for Injection, 15g, USP
Abraxis BioScience Receives FDA Approval for Ampicillin and Sulbactam for Injection, 15g, USP
HSMN NewsFeed - 28 Nov 2006
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial
HSMN NewsFeed - 28 Nov 2006
Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
HSMN NewsFeed - 28 Nov 2006
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
HSMN NewsFeed - 28 Nov 2006
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
HSMN NewsFeed - 28 Nov 2006
Quinnova Pharmaceuticals, Inc. Completes $13.6 Million Series A Financing
Quinnova Pharmaceuticals, Inc. Completes $13.6 Million Series A Financing
HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
HSMN NewsFeed - 27 Nov 2006
Acumen Pharmaceuticals Announces Amended Agreement with Merck to Include Exclusive Diagnostic Rights
Acumen Pharmaceuticals Announces Amended Agreement with Merck to Include Exclusive Diagnostic Rights
HSMN NewsFeed - 27 Nov 2006
Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
HSMN NewsFeed - 27 Nov 2006
Biota and Boehringer Ingelheim Complete US$102 Million License for HCV Program
Biota and Boehringer Ingelheim Complete US$102 Million License for HCV Program
HSMN NewsFeed - 27 Nov 2006
Alimera Sciences Completes Second Tranche of Series B Financing, Receives $15.9 Million
Alimera Sciences Completes Second Tranche of Series B Financing, Receives $15.9 Million
HSMN NewsFeed - 27 Nov 2006
Dr. Stephen Freedman Joins Ingenium as Executive Vice President, Corporate Development
Dr. Stephen Freedman Joins Ingenium as Executive Vice President, Corporate Development
HSMN NewsFeed - 23 Nov 2006
Betaferon(R) Approved in Australia for Earliest Stages of Multiple Sclerosis
Betaferon(R) Approved in Australia for Earliest Stages of Multiple Sclerosis
HSMN NewsFeed - 22 Nov 2006
The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results
The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results
HSMN NewsFeed - 22 Nov 2006
OctoPlus Grants Green Cross Corporation Exclusive Korean License to OP-145 for Chronic Middle ear Infection
OctoPlus Grants Green Cross Corporation Exclusive Korean License to OP-145 for Chronic Middle ear Infection
HSMN NewsFeed - 21 Nov 2006
Teva Announces Agreement with Pfizer Regarding Idarubicin, Azithromycin, and Epirubicin
Teva Announces Agreement with Pfizer Regarding Idarubicin, Azithromycin, and Epirubicin
HSMN NewsFeed - 21 Nov 2006
Pfizer Announces Settlement With Teva on Patents Covering Cancer Medicine and Antibiotic
Pfizer Announces Settlement With Teva on Patents Covering Cancer Medicine and Antibiotic
HSMN NewsFeed - 21 Nov 2006
Altus Pharmaceuticals Appoints Shire Executive David Pendergast to Board of Directors
Altus Pharmaceuticals Appoints Shire Executive David Pendergast to Board of Directors
HSMN NewsFeed - 21 Nov 2006
US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP
US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP
HSMN NewsFeed - 21 Nov 2006
Repligen Receives Orphan Drug Designation from the FDA for RG1068 for MRI Imaging of the Pancreas
Repligen Receives Orphan Drug Designation from the FDA for RG1068 for MRI Imaging of the Pancreas
HSMN NewsFeed - 21 Nov 2006
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
HSMN NewsFeed - 21 Nov 2006
Santarus Announces Effective Date of OTC License Agreement with Schering-Plough
Santarus Announces Effective Date of OTC License Agreement with Schering-Plough
HSMN NewsFeed - 21 Nov 2006
Pharmion and Nippon Shinyaku Announce Licensing Agreement for Vidaza(R) in Japan
Pharmion and Nippon Shinyaku Announce Licensing Agreement for Vidaza(R) in Japan
HSMN NewsFeed - 20 Nov 2006
Auxilium Pharmaceuticals, Inc. Initiates Phase III Trials for AA4500 in Dupuytren's Contracture
Auxilium Pharmaceuticals, Inc. Initiates Phase III Trials for AA4500 in Dupuytren's Contracture
HSMN NewsFeed - 20 Nov 2006
Anadys Pharmaceuticals Names Lawrence C. Fritz, Ph.D., as President and Chief Executive Officer
Anadys Pharmaceuticals Names Lawrence C. Fritz, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 20 Nov 2006
Pharmacyclics Announces Presentation of Pooled Analysis of Xcytrin(R) for Lung Cancer Brain Metastases
Pharmacyclics Announces Presentation of Pooled Analysis of Xcytrin(R) for Lung Cancer Brain Metastases
HSMN NewsFeed - 20 Nov 2006
Gliadel(R) Wafer Clinical Data Presented at Society for Neuro-Oncology Meeting
Gliadel(R) Wafer Clinical Data Presented at Society for Neuro-Oncology Meeting
HSMN NewsFeed - 20 Nov 2006
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
HSMN NewsFeed - 20 Nov 2006
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
HSMN NewsFeed - 17 Nov 2006
Fougera Receives Approval for First Generic Sulfacetamide Sodium Topical Suspension USP 10% (Rx)
Fougera Receives Approval for First Generic Sulfacetamide Sodium Topical Suspension USP 10% (Rx)
HSMN NewsFeed - 17 Nov 2006
Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
HSMN NewsFeed - 15 Nov 2006
Ambrilia Announces European Licensing Partnership with TEVA for its Lead Oncology Product, Octreotide
Ambrilia Announces European Licensing Partnership with TEVA for its Lead Oncology Product, Octreotide
HSMN NewsFeed - 15 Nov 2006
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
HSMN NewsFeed - 15 Nov 2006
Chiasma Raises $44 Million Series C to Fund Clinical Testing, Advance Technology
Chiasma Raises $44 Million Series C to Fund Clinical Testing, Advance Technology
HSMN NewsFeed - 15 Nov 2006
Replidyne Appoints Vice President, Manufacturing and Director, Investor Relations
Replidyne Appoints Vice President, Manufacturing and Director, Investor Relations
HSMN NewsFeed - 15 Nov 2006
Cobalt Announces Settlement of Imitrex(R) Litigation With GlaxoSmithKline
Cobalt Announces Settlement of Imitrex(R) Litigation With GlaxoSmithKline
HSMN NewsFeed - 15 Nov 2006
Bayhill Therapeutics Names Robert S. King Vice President of Manufacturing
Bayhill Therapeutics Names Robert S. King Vice President of Manufacturing
HSMN NewsFeed - 14 Nov 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
HSMN NewsFeed - 14 Nov 2006
Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care
Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care
HSMN NewsFeed - 14 Nov 2006
Medicure Announces New AGGRASTAT(R) Data at 2006 Scientific Sessions of the American Heart Association
Medicure Announces New AGGRASTAT(R) Data at 2006 Scientific Sessions of the American Heart Association
HSMN NewsFeed - 14 Nov 2006
Abbott Laboratories Commences Tender Offer for All Outstanding Shares of Kos Pharmaceuticals, Inc.
Abbott Laboratories Commences Tender Offer for All Outstanding Shares of Kos Pharmaceuticals, Inc.
HSMN NewsFeed - 14 Nov 2006
Inovio Biomedical Grants VGX Pharmaceuticals License to Develop Novel Cancer Therapeutic
Inovio Biomedical Grants VGX Pharmaceuticals License to Develop Novel Cancer Therapeutic
HSMN NewsFeed - 13 Nov 2006
Somaxon Pharmaceuticals Names Brian Dorsey Vice President of Manufacturing and Program Management
Somaxon Pharmaceuticals Names Brian Dorsey Vice President of Manufacturing and Program Management
HSMN NewsFeed - 13 Nov 2006
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
HSMN NewsFeed - 13 Nov 2006
Approved Asthma Therapy SYMBICORT Improves Lung Function Safely and Effectively
Approved Asthma Therapy SYMBICORT Improves Lung Function Safely and Effectively
HSMN NewsFeed - 13 Nov 2006
Anika Therapeutics Appoints Constance Garrison as Vice President of Regulatory and Clinical Affairs
Anika Therapeutics Appoints Constance Garrison as Vice President of Regulatory and Clinical Affairs
HSMN NewsFeed - 13 Nov 2006
Treatment of Diabetic Foot Ulcers to Be Addressed at Upcoming American Heart Association Meeting
Treatment of Diabetic Foot Ulcers to Be Addressed at Upcoming American Heart Association Meeting
HSMN NewsFeed - 13 Nov 2006
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
HSMN NewsFeed - 13 Nov 2006
Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine
Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine
HSMN NewsFeed - 13 Nov 2006
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
HSMN NewsFeed - 13 Nov 2006
Vion Pharmaceuticals Reaches Midpoint of Patient Accrual to Cloretazine(R) (VNP40101M) Phase III Trial
Vion Pharmaceuticals Reaches Midpoint of Patient Accrual to Cloretazine(R) (VNP40101M) Phase III Trial
HSMN NewsFeed - 13 Nov 2006
Auriga Laboratories Appoints Charles R. Bearchell as Chief Financial Officer
Auriga Laboratories Appoints Charles R. Bearchell as Chief Financial Officer
HSMN NewsFeed - 13 Nov 2006
Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
HSMN NewsFeed - 13 Nov 2006
XOPENEX HFA(R) Data Presented at American College of Allergy, Asthma and Immunology Annual Meeting
XOPENEX HFA(R) Data Presented at American College of Allergy, Asthma and Immunology Annual Meeting
HSMN NewsFeed - 10 Nov 2006
IMPAX Receives Final FDA Approval and First-to-File Status for Generic Version of Ditropan(R) XL 15 mg
IMPAX Receives Final FDA Approval and First-to-File Status for Generic Version of Ditropan(R) XL 15 mg
HSMN NewsFeed - 10 Nov 2006
Cardinal Health Names Mark Parrish CEO of Healthcare Supply Chain Services
Cardinal Health Names Mark Parrish CEO of Healthcare Supply Chain Services
HSMN NewsFeed - 10 Nov 2006
Merck Responds to FDA-Issued Approvable Letters for Arcoxia(R) (etoricoxib)
Merck Responds to FDA-Issued Approvable Letters for Arcoxia(R) (etoricoxib)
HSMN NewsFeed - 10 Nov 2006
FDA Approves MIRAPEX for the Treatment of Moderate-to-Severe Primary Restless Legs Syndrome
FDA Approves MIRAPEX for the Treatment of Moderate-to-Severe Primary Restless Legs Syndrome
HSMN NewsFeed - 10 Nov 2006
Mylan Receives Final FDA Approval for Oxybutynin Chloride Extended-release Tablets
Mylan Receives Final FDA Approval for Oxybutynin Chloride Extended-release Tablets
HSMN NewsFeed - 10 Nov 2006
NicOx receives FDA feedback that no cardiovascular outcomes study required for naproxcinod NDA
NicOx receives FDA feedback that no cardiovascular outcomes study required for naproxcinod NDA
HSMN NewsFeed - 9 Nov 2006
Ivivi Technologies and Allergan Enter into Worldwide Distribution Agreement
Ivivi Technologies and Allergan Enter into Worldwide Distribution Agreement
HSMN NewsFeed - 9 Nov 2006
Bayer Outlines New Global R&D Structures; U.S. Pharma Sites and Future Headquarters
Bayer Outlines New Global R&D Structures; U.S. Pharma Sites and Future Headquarters
HSMN NewsFeed - 9 Nov 2006
Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
HSMN NewsFeed - 9 Nov 2006
Study in Today's New England Journal of Medicine Shows Benefits of Thymoglobulin Use
Study in Today's New England Journal of Medicine Shows Benefits of Thymoglobulin Use
HSMN NewsFeed - 9 Nov 2006
Neurobiological Technologies, Inc. Comments on Recent Stroke Trial Developments
Neurobiological Technologies, Inc. Comments on Recent Stroke Trial Developments
HSMN NewsFeed - 9 Nov 2006
Graceway Pharmaceuticals to Acquire 3M Pharmaceuticals Business in North and Latin America
Graceway Pharmaceuticals to Acquire 3M Pharmaceuticals Business in North and Latin America
HSMN NewsFeed - 8 Nov 2006
Halozyme Therapeutics Names William Fallon Vice President, Manufacturing & Operations
Halozyme Therapeutics Names William Fallon Vice President, Manufacturing & Operations
HSMN NewsFeed - 8 Nov 2006
BioSante Pharmaceuticals Signs Bio-E-Gel(R) Marketing Agreement With Bradley Pharmaceuticals, Inc.
BioSante Pharmaceuticals Signs Bio-E-Gel(R) Marketing Agreement With Bradley Pharmaceuticals, Inc.
HSMN NewsFeed - 8 Nov 2006
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial
HSMN NewsFeed - 7 Nov 2006
Callisto Pharmaceuticals Initiates Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer
Callisto Pharmaceuticals Initiates Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer
HSMN NewsFeed - 7 Nov 2006
Daniel B. Soland Joins ViroPharma as Vice President and Chief Commercial Officer
Daniel B. Soland Joins ViroPharma as Vice President and Chief Commercial Officer
HSMN NewsFeed - 7 Nov 2006
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
HSMN NewsFeed - 7 Nov 2006
Inovio Biomedical Grants Wyeth Pharmaceuticals License to Develop Infectious Disease DNA Vaccines
Inovio Biomedical Grants Wyeth Pharmaceuticals License to Develop Infectious Disease DNA Vaccines
HSMN NewsFeed - 6 Nov 2006
PDI, Inc. Announces Appointment of David N. Stievater as Senior Vice President, Emerging Pharma
PDI, Inc. Announces Appointment of David N. Stievater as Senior Vice President, Emerging Pharma
HSMN NewsFeed - 6 Nov 2006
Mayne Pharma (USA) Inc. Announces the Launch of Epirubicin Hydrochloride for Injection
Mayne Pharma (USA) Inc. Announces the Launch of Epirubicin Hydrochloride for Injection
HSMN NewsFeed - 6 Nov 2006
Barr Launches Plan B(R) OTC/Rx Dual-Label Product; Awarded 3 Years New Product Exclusivity
Barr Launches Plan B(R) OTC/Rx Dual-Label Product; Awarded 3 Years New Product Exclusivity
HSMN NewsFeed - 6 Nov 2006
ARCA Discovery Names Richard B. Brewer President and Chief Executive Officer
ARCA Discovery Names Richard B. Brewer President and Chief Executive Officer
HSMN NewsFeed - 6 Nov 2006
Indevus Announces Licensing and Manufacturing Pact for SANCTURA XR(TM) With Madaus GmbH
Indevus Announces Licensing and Manufacturing Pact for SANCTURA XR(TM) With Madaus GmbH
HSMN NewsFeed - 6 Nov 2006
Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pharmaceuticals
Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pharmaceuticals
HSMN NewsFeed - 6 Nov 2006
Geron Licenses Antigen Targeting Patents for Cancer Vaccine Program from Immunomic Therapeutics
Geron Licenses Antigen Targeting Patents for Cancer Vaccine Program from Immunomic Therapeutics
HSMN NewsFeed - 6 Nov 2006
Pharmacopeia Announces the Appointment of Vice President, Clinical and Regulatory Affairs
Pharmacopeia Announces the Appointment of Vice President, Clinical and Regulatory Affairs
HSMN NewsFeed - 6 Nov 2006
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
HSMN NewsFeed - 3 Nov 2006
Corautus Genetics Announces Redirection of Focus and Transition Of Officers
Corautus Genetics Announces Redirection of Focus and Transition Of Officers
HSMN NewsFeed - 3 Nov 2006
Santarus and inVentiv Health Announce Agreement to Add Representatives to Santarus' ZEGERID Sales Team
Santarus and inVentiv Health Announce Agreement to Add Representatives to Santarus' ZEGERID Sales Team
HSMN NewsFeed - 3 Nov 2006
PTC Therapeutics Announces Positive Phase 2 Results For PTC124 in Cystic Fibrosis
PTC Therapeutics Announces Positive Phase 2 Results For PTC124 in Cystic Fibrosis
HSMN NewsFeed - 2 Nov 2006
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
HSMN NewsFeed - 2 Nov 2006
Ranbaxy Receives Tentative Approval to Manufacture and Market Cetirizine Hydrochloride Syrup
Ranbaxy Receives Tentative Approval to Manufacture and Market Cetirizine Hydrochloride Syrup
HSMN NewsFeed - 2 Nov 2006
Study Shows Ambrilia's PSP94 Immunoassay to Have Prognostic Value in Prostate Cancer Management
Study Shows Ambrilia's PSP94 Immunoassay to Have Prognostic Value in Prostate Cancer Management
HSMN NewsFeed - 2 Nov 2006
Osteologix Granted European Patent for Treating Cartilage and Bone Conditions
Osteologix Granted European Patent for Treating Cartilage and Bone Conditions
HSMN NewsFeed - 2 Nov 2006
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
HSMN NewsFeed - 2 Nov 2006
Bentley Pharmaceuticals Expands Phase II Clinical Trials of Intranasal Insulin Spray to the U.S.
Bentley Pharmaceuticals Expands Phase II Clinical Trials of Intranasal Insulin Spray to the U.S.
HSMN NewsFeed - 2 Nov 2006
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Submitted to FDA
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Submitted to FDA
HSMN NewsFeed - 2 Nov 2006
Exelixis Suspends Enrollment of New Patients in XL999 Phase II Clinical Trial Program
Exelixis Suspends Enrollment of New Patients in XL999 Phase II Clinical Trial Program
HSMN NewsFeed - 1 Nov 2006
Report Calls for Using Heated Chemotherapy after Colon Cancer Surgery to Optimize Patient Survival
Report Calls for Using Heated Chemotherapy after Colon Cancer Surgery to Optimize Patient Survival
HSMN NewsFeed - 1 Nov 2006
VIVUS Appoints Changjin (CJ) Wang, Ph.D. as Vice President of Business Development
VIVUS Appoints Changjin (CJ) Wang, Ph.D. as Vice President of Business Development
HSMN NewsFeed - 1 Nov 2006
IMS Health Names Bruce Boggs Senior Vice President, Global Marketing and External Affairs
IMS Health Names Bruce Boggs Senior Vice President, Global Marketing and External Affairs
HSMN NewsFeed - 1 Nov 2006
Carrington's DelSite Subsidiary Presents Data on Needle-Free Vaccine Technology
Carrington's DelSite Subsidiary Presents Data on Needle-Free Vaccine Technology
HSMN NewsFeed - 1 Nov 2006
Merck's Cervical Cancer Vaccine, GARDASIL(R), Added to the CDC Vaccines for Children Contract
Merck's Cervical Cancer Vaccine, GARDASIL(R), Added to the CDC Vaccines for Children Contract
HSMN NewsFeed - 1 Nov 2006
Cellgate Commences Phase II Clinical Trial of Anticancer Compound CGC-11047 for Prostate Cancer
Cellgate Commences Phase II Clinical Trial of Anticancer Compound CGC-11047 for Prostate Cancer
HSMN NewsFeed - 1 Nov 2006
Pharmion Corporation Announces Enrollment of First Patient Into Vidaza(R) Patient Registry
Pharmion Corporation Announces Enrollment of First Patient Into Vidaza(R) Patient Registry
HSMN NewsFeed - 1 Nov 2006
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
HSMN NewsFeed - 1 Nov 2006
Avalon Pharmaceuticals Names Todd R. Golub, M.D. as Chairman and Member of Its Scientific Advisory Board
Avalon Pharmaceuticals Names Todd R. Golub, M.D. as Chairman and Member of Its Scientific Advisory Board
HSMN NewsFeed - 1 Nov 2006
Pharming Shareholders Appoint Bruno Giannetti as Member of the Board of Management
Pharming Shareholders Appoint Bruno Giannetti as Member of the Board of Management
HSMN NewsFeed - 1 Nov 2006
Synovics Pharmaceuticals Initiates U.S. Development of Its Fourth Generic Oral Controlled-Release Drug
Synovics Pharmaceuticals Initiates U.S. Development of Its Fourth Generic Oral Controlled-Release Drug
HSMN NewsFeed - 1 Nov 2006
MediciNova Announces the Acquisition of Two Novel Antithrombotic Agents from Meiji Seika Kaisha, Ltd.
MediciNova Announces the Acquisition of Two Novel Antithrombotic Agents from Meiji Seika Kaisha, Ltd.
HSMN NewsFeed - 1 Nov 2006
EpiCept Announces Successful Validation of Marketing Authorization Application for Ceplene(TM)
EpiCept Announces Successful Validation of Marketing Authorization Application for Ceplene(TM)
HSMN NewsFeed - 31 Oct 2006
Boehringer Ingelheim Launches PROUD Study to Explore Possible Disease-Modifying Effect of Pramipexole
Boehringer Ingelheim Launches PROUD Study to Explore Possible Disease-Modifying Effect of Pramipexole
HSMN NewsFeed - 31 Oct 2006
CytRx's Arimoclomol Granted Orphan Drug Designation in European Union for Treatment of ALS
CytRx's Arimoclomol Granted Orphan Drug Designation in European Union for Treatment of ALS
HSMN NewsFeed - 31 Oct 2006
Jody LoMenzo Named Director, Investor Relations and Corporate Communications
Jody LoMenzo Named Director, Investor Relations and Corporate Communications
HSMN NewsFeed - 31 Oct 2006
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed - 31 Oct 2006
GammaCan International, Announces Appointment of Lynn Schuchter M.D. to its Scientific Advisory Board
GammaCan International, Announces Appointment of Lynn Schuchter M.D. to its Scientific Advisory Board
HSMN NewsFeed - 31 Oct 2006
Advancis Pharmaceutical Submits Proposed Order in Corporate Name Infringement Lawsuit
Advancis Pharmaceutical Submits Proposed Order in Corporate Name Infringement Lawsuit
HSMN NewsFeed - 30 Oct 2006
ARCA Discovery, Inc. Names Thomas Keuer Executive Vice President of Pharmaceutical Operations
ARCA Discovery, Inc. Names Thomas Keuer Executive Vice President of Pharmaceutical Operations
HSMN NewsFeed - 30 Oct 2006
Avantogen Oncology Inc. Announces FDA Acceptance Of Its IND For The Novel Cancer Drug Candidate, RP101
Avantogen Oncology Inc. Announces FDA Acceptance Of Its IND For The Novel Cancer Drug Candidate, RP101
HSMN NewsFeed - 30 Oct 2006
Repligen Reports Initiation of a Clinical Study of Secretin for Functional MRI Assessment of the Pancreas
Repligen Reports Initiation of a Clinical Study of Secretin for Functional MRI Assessment of the Pancreas
HSMN NewsFeed - 28 Oct 2006
PAION AG: Data Monitoring Committee Lifts Hold on PAION's Phase III Stroke Study DIAS-2
PAION AG: Data Monitoring Committee Lifts Hold on PAION's Phase III Stroke Study DIAS-2
HSMN NewsFeed - 27 Oct 2006
Dendreon Presents New Data Correlating Potency of PROVENGE to Survival in Phase 3 Studies
Dendreon Presents New Data Correlating Potency of PROVENGE to Survival in Phase 3 Studies
HSMN NewsFeed - 27 Oct 2006
Customizing Treatment with PEGASYS(R) May Improve Chances for Success in Hepatitis C
Customizing Treatment with PEGASYS(R) May Improve Chances for Success in Hepatitis C
HSMN NewsFeed - 27 Oct 2006
S*BIO Appoints Joy Zhu Senior Vice President of Global Clinical Development
S*BIO Appoints Joy Zhu Senior Vice President of Global Clinical Development
HSMN NewsFeed - 27 Oct 2006
Elite Holds Clinical Guidance Meeting with the FDA on Its Abuse Deterrent Pain Program
Elite Holds Clinical Guidance Meeting with the FDA on Its Abuse Deterrent Pain Program
HSMN NewsFeed - 27 Oct 2006
NicOx Naproxcinod Phase 3 OA Trial Meets Primary Endpoints and Shows Encouraging Blood Pressure Profile
NicOx Naproxcinod Phase 3 OA Trial Meets Primary Endpoints and Shows Encouraging Blood Pressure Profile
HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
HSMN NewsFeed - 26 Oct 2006
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
HSMN NewsFeed - 26 Oct 2006
TAXUS(R) stents demonstrate excellent efficacy and safety in studies presented at TCT 2006
TAXUS(R) stents demonstrate excellent efficacy and safety in studies presented at TCT 2006
HSMN NewsFeed - 26 Oct 2006
CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2006
CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2006
HSMN NewsFeed - 26 Oct 2006
Idenix Pharmaceuticals Announces Strategic Collaboration To Enhance Hepatitis C Pipeline
Idenix Pharmaceuticals Announces Strategic Collaboration To Enhance Hepatitis C Pipeline
HSMN NewsFeed - 26 Oct 2006
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
HSMN NewsFeed - 26 Oct 2006
Cleveland BioLabs President and CEO Provides Update on Clinical and Corporate Developments
Cleveland BioLabs President and CEO Provides Update on Clinical and Corporate Developments
HSMN NewsFeed - 26 Oct 2006
Ilypsa Announces Appointment of William D. Waddill as Chief Financial Officer
Ilypsa Announces Appointment of William D. Waddill as Chief Financial Officer
HSMN NewsFeed - 26 Oct 2006
Koronis Pharmaceuticals Appoints Stephen Becker, M.D., Chief Medical Officer
Koronis Pharmaceuticals Appoints Stephen Becker, M.D., Chief Medical Officer
HSMN NewsFeed - 26 Oct 2006
Cleveland BioLabs Appoints John Gordon, Ph.D. Director of Clinical Operations
Cleveland BioLabs Appoints John Gordon, Ph.D. Director of Clinical Operations
HSMN NewsFeed - 26 Oct 2006
Arrowhead Subsidiary, Insert Therapeutics, Inc., Raises $10 Million in Private Equity Financing
Arrowhead Subsidiary, Insert Therapeutics, Inc., Raises $10 Million in Private Equity Financing
HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
HSMN NewsFeed - 26 Oct 2006
NXY-059 Does Not Meet Efficacy Endpoints in Phase III Trial for Acute Ischemic Stroke
NXY-059 Does Not Meet Efficacy Endpoints in Phase III Trial for Acute Ischemic Stroke
HSMN NewsFeed - 25 Oct 2006
Eisai Announces Completion of Acquisition of Four Oncology-Related Products from Ligand
Eisai Announces Completion of Acquisition of Four Oncology-Related Products from Ligand
HSMN NewsFeed - 25 Oct 2006
Vasogen's ACCLAIM Trial of Celacade(TM) in Heart Failure Presented at the Canadian Cardiovascular Congress
Vasogen's ACCLAIM Trial of Celacade(TM) in Heart Failure Presented at the Canadian Cardiovascular Congress
HSMN NewsFeed - 25 Oct 2006
Caprion Pharmaceuticals Announces Expansion of Biomarker Discovery Collaboration with Vertex Pharmaceuticals
Caprion Pharmaceuticals Announces Expansion of Biomarker Discovery Collaboration with Vertex Pharmaceuticals
HSMN NewsFeed - 25 Oct 2006
Affymax Appoints Grace U. Shin as Vice President of Legal Affairs and Corporate Counsel
Affymax Appoints Grace U. Shin as Vice President of Legal Affairs and Corporate Counsel
HSMN NewsFeed - 24 Oct 2006
CardioVascular BioTherapeutics Initiates Study on the Treatment of Peripheral Artery Disease
CardioVascular BioTherapeutics Initiates Study on the Treatment of Peripheral Artery Disease
HSMN NewsFeed - 24 Oct 2006
ProNAi Closes Successful Bridge Funding Round, Secures $6.65 Million Total
ProNAi Closes Successful Bridge Funding Round, Secures $6.65 Million Total
HSMN NewsFeed - 24 Oct 2006
Cyclacel Pharmaceuticals Names John Womelsdorf, Ph.D., Vice President, Business Development
Cyclacel Pharmaceuticals Names John Womelsdorf, Ph.D., Vice President, Business Development
HSMN NewsFeed - 24 Oct 2006
Targacept Announces Addition of Alan W. Dunton, M.D. to Its Board of Directors
Targacept Announces Addition of Alan W. Dunton, M.D. to Its Board of Directors
HSMN NewsFeed - 24 Oct 2006
Acuity Pharmaceuticals Appoints Denis O'Shaughnessy Senior Vice President of Clinical Development
Acuity Pharmaceuticals Appoints Denis O'Shaughnessy Senior Vice President of Clinical Development
HSMN NewsFeed - 24 Oct 2006
Repros Reports Partial Interim Assessment of Phase 2 Study of Proellex(TM) in Endometriosis
Repros Reports Partial Interim Assessment of Phase 2 Study of Proellex(TM) in Endometriosis
HSMN NewsFeed - 24 Oct 2006
Cambrex Announces Sale of Bioproducts and Biopharma Subsidiaries to Lonza for $460 Million In Cash
Cambrex Announces Sale of Bioproducts and Biopharma Subsidiaries to Lonza for $460 Million In Cash
HSMN NewsFeed - 23 Oct 2006
Advancis Pharmaceutical Announces Promotion of Robert C. Low to Chief Financial Officer
Advancis Pharmaceutical Announces Promotion of Robert C. Low to Chief Financial Officer
HSMN NewsFeed - 23 Oct 2006
U.S. Appeals Court Denies Ranbaxy Petition for Rehearing Regarding Main Patent in Lipitor Case
U.S. Appeals Court Denies Ranbaxy Petition for Rehearing Regarding Main Patent in Lipitor Case
HSMN NewsFeed - 23 Oct 2006
FDA Approves Betaseron(R) for Use After the First Event Suggestive of Multiple Sclerosis
FDA Approves Betaseron(R) for Use After the First Event Suggestive of Multiple Sclerosis
HSMN NewsFeed - 23 Oct 2006
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
HSMN NewsFeed - 23 Oct 2006
Salix Pharmaceuticals Reports American College of Gastroenterology Update
Salix Pharmaceuticals Reports American College of Gastroenterology Update
HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
HSMN NewsFeed - 23 Oct 2006
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
HSMN NewsFeed - 23 Oct 2006
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
Connetics Corporation and Stiefel Laboratories, Inc. Sign Definitive Merger Agreement
HSMN NewsFeed - 23 Oct 2006
ALTANA Pharma Receives Approval to Market Ciclesonide Nasal Spray in The U.S.
ALTANA Pharma Receives Approval to Market Ciclesonide Nasal Spray in The U.S.
HSMN NewsFeed - 21 Oct 2006
PTC Therapeutics Announces Encouraging Preliminary Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
PTC Therapeutics Announces Encouraging Preliminary Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
HSMN NewsFeed - 20 Oct 2006
FDA Approves New, Once-a-Day COREG CR(TM) for the Treatment of Three Key Cardiovascular Conditions
FDA Approves New, Once-a-Day COREG CR(TM) for the Treatment of Three Key Cardiovascular Conditions
HSMN NewsFeed - 20 Oct 2006
U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit
U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit
HSMN NewsFeed - 20 Oct 2006
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
HSMN NewsFeed - 20 Oct 2006
Indevus Announces the Finalization of Supply Agreement with Schering AG, Germany for NEBIDO(R)
Indevus Announces the Finalization of Supply Agreement with Schering AG, Germany for NEBIDO(R)
HSMN NewsFeed - 20 Oct 2006
FDA Approves Prescription Zaditor(R) for Over-The-Counter Relief From Itchy Eyes
FDA Approves Prescription Zaditor(R) for Over-The-Counter Relief From Itchy Eyes
HSMN NewsFeed - 20 Oct 2006
Newly Trained ESSURE(R) Physicians Achieve 94.6 Percent Bilateral Placement Success
Newly Trained ESSURE(R) Physicians Achieve 94.6 Percent Bilateral Placement Success
HSMN NewsFeed - 20 Oct 2006
Lilly Launches Phase III 'GALES' Trial of ALIMTA(R) (Pemetrexed for Injection) in Small Cell Lung Cancer
Lilly Launches Phase III 'GALES' Trial of ALIMTA(R) (Pemetrexed for Injection) in Small Cell Lung Cancer
HSMN NewsFeed - 20 Oct 2006
Barr Acquires PLIVA d.d. Following Official Closing of Tender Offer Process
Barr Acquires PLIVA d.d. Following Official Closing of Tender Offer Process
HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
HSMN NewsFeed - 19 Oct 2006
PharmaNova Grants Exclusive U.S. License to Depomed for Extended Release Gabapentin Use in Hot Flashes
PharmaNova Grants Exclusive U.S. License to Depomed for Extended Release Gabapentin Use in Hot Flashes
HSMN NewsFeed - 19 Oct 2006
Fresenius Medical Care Announces New Sourcing and Supply Agreement with Amgen
Fresenius Medical Care Announces New Sourcing and Supply Agreement with Amgen
HSMN NewsFeed - 18 Oct 2006
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
HSMN NewsFeed - 18 Oct 2006
CardioVascular BioTherapeutics Appoints Mike Norris Vice President of Business Development
CardioVascular BioTherapeutics Appoints Mike Norris Vice President of Business Development
HSMN NewsFeed - 18 Oct 2006
AVI BioPharma Initiates NEUGENE Antisense Clinical Program in Coronary Artery Bypass Grafting
AVI BioPharma Initiates NEUGENE Antisense Clinical Program in Coronary Artery Bypass Grafting
HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
HSMN NewsFeed - 18 Oct 2006
NeurogesX Phase 3 Study in Post-Herpetic Neuralgia Meets Primary Endpoint
NeurogesX Phase 3 Study in Post-Herpetic Neuralgia Meets Primary Endpoint
HSMN NewsFeed - 18 Oct 2006
Santarus Licenses OTC Rights to Lower Dosage Immediate-Release ZEGERID Products to Schering-Plough
Santarus Licenses OTC Rights to Lower Dosage Immediate-Release ZEGERID Products to Schering-Plough
HSMN NewsFeed - 17 Oct 2006
Indevus Pharmaceuticals Announces Appointment of Thomas Farb as President and Chief Operating Officer
Indevus Pharmaceuticals Announces Appointment of Thomas Farb as President and Chief Operating Officer
HSMN NewsFeed - 17 Oct 2006
ICOS Corporation Announces Agreement to be Acquired by Eli Lilly and Company
ICOS Corporation Announces Agreement to be Acquired by Eli Lilly and Company
HSMN NewsFeed - 17 Oct 2006
Acorda Therapeutics Announces Expansion of Zanaflex Capsules(TM) Sales Force to 65
Acorda Therapeutics Announces Expansion of Zanaflex Capsules(TM) Sales Force to 65
HSMN NewsFeed - 17 Oct 2006
Inovio Biomedical Acquires Rights to DNA Vaccine Licenses and Intellectual Property from Valentis
Inovio Biomedical Acquires Rights to DNA Vaccine Licenses and Intellectual Property from Valentis
HSMN NewsFeed - 17 Oct 2006
Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent
Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent
